Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04913454
Other study ID # 2021-00989
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 1, 2021
Est. completion date July 31, 2022

Study information

Verified date May 2021
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to the most popular pathophysiological models of Alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which finally lead to Alzheimer's disease and dementia. In mouse models of Alzheimer's disease, 40 Hz multi-sensory (auditory and visual) stimulation was able to reduce the number and size of amyloid plaques throughout cortex and improve cognitive performance. The primary objective of this study is to assess whether an intervention consisting of 40 Hz multi-sensory (auditory and visual) stimulation is able to reduce the amyloid load in non-demented amyloid-positive individuals. As secondary objectives, the investigators will assess whether such intervention is able to: - improve the brain electrical activity, - improve or slow down the worsening of Alzheimer's blood-based biomarkers, - improve or slow down the worsening of cognition.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date July 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - Informed Consent as documented by signature (Appendix Informed Consent Form), - age 40-80, - =5 years of education, - previous evidence of brain amyloidosis (assessed by PET, CSF, or blood-based biomarkers). Exclusion Criteria: - history of epilepsy; - clinically relevant visual or auditory diseases/deficits; - clinical diagnosis of dementia; - contraindication to amyloid-PET; - inability to undergo the procedures of the study, e.g. severe behavioral disturbances; - severe diseases: 1. Malignant neoplasm within 5 years, 2. Life threatening diseases, 3. Severe systemic diseases (e.g. kidney insufficiency, cardiac insufficiency, decompensated diabetes, decompensated metabolic diseases, decompensated hypothyroidism, uncontrolled autoimmune diseases); - the participation to a clinical trial involving potential Alzheimer's disease modifying therapies; - documented pregnancy or intention to become pregnant during the course of the study or breast feeding.

Study Design


Intervention

Other:
40 Hz multi-sensory (auditory + visual) stimulation and cognitive training
40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
Cognitive training
Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Geneva

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in amyloid load Changes in amyloid load assessed by longitudinal amyloid-PET 8 weeks
Secondary Changes in brain electrical activity Changes in brain electrical activity (e.g. gamma power spectral density) assessed by longitudinal EEG 8 weeks
Secondary Changes in Alzheimer's blood-based biomarkers Changes in Alzheimer's blood-based biomarkers (e.g. plasma Aß42/Aß40 ratio, Aß42, Aß40, p-tau, and neurofilament light) assessed by longitudinal blood sample collection 8 weeks
Secondary Changes in cognition Changes in cognition (using the Preclinical Alzheimer Cognitive Composite (PACC) score) assessed by longitudinal neuropsychological assessment 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A